Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Acutus Medical, Inc. AFIB

Healthcare — Medical Devices
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
36.37%

Capital & Financial Ratios

Market Cap
1.69
Revenue
20.16
Net Income
(9.55)
Free Cash Flow
(31.77)
Net Debt
18.55
Current Ratio
2.06
Debt/Equity
(2.81)
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
0.00
Past 5Y EPS Growth
(9.95%)
This Y EPS Growth
(280.49%)
Next Y EPS Growth
34.60%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2021 2022 2023 2024
Cash 100.92 76.21 29.43 14.02
Receivables 3.63 17.92 11.35 7.88
Inventory 16.41 1.79 4.28 1.79
Other 4.43 4.70 — —
126.29 117.87 46.25 25.58
2021 2022 2023 2024
Payables 7.52 2.47 2.76 1.28
ST’ Debt 0.40 0.32 1.86 7.01
Other 1.50 5.15 0.41 0.19
18.51 19.87 18.94 12.44
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’24 3.63 4.13 5.27 7.14
20.16
’23 1.24 1.52 2.06 2.35
7.16
’22 3.68 4.08 3.64 (8.37)
3.03
’21 3.59 4.71 4.60 4.36
17.26
’20 1.58 1.13 3.17 2.57
8.46
’19 0.79 0.73 0.65 0.67
2.84
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’24 (16.93) (6.97) (3.70) (4.06)
(31.66)
’23 (15.73) (15.37) (14.01) (18.01)
(63.12)
’22 (27.61) (23.10) (21.35) (16.86)
(88.92)
’21 (26.27) (23.64) (27.19) (22.58)
(99.68)
’20 (17.56) (17.20) (26.28) (24.13)
(85.17)
’19 (9.58) (12.50) (8.74) (25.16)
(55.99)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’24 (17.03) (7.01) (3.70) (4.02)
(31.77)
’23 (15.75) (16.12) (14.42) (17.04)
(63.34)
’22 (28.70) (23.73) (22.10) (14.62)
(89.14)
’21 (29.97) (25.79) (27.93) (25.97)
(109.65)
’20 (19.24) (19.96) (29.65) (27.53)
(96.39)
’19 (9.61) (12.79) (19.11) (27.87)
(69.38)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 — — — —
—
’24 (0.06) (0.03) (0.19) —
(0.32)
’23 (0.57) (0.63) (0.45) —
(2.81)
’22 (1.42) 0.16 (0.72) 0.41
(1.40)
’21 (1.04) (1.02) (0.94) (1.12)
(4.11)
’20 (0.66) (32.24) (1.95) (1.05)
(8.94)
’19 (0.54) — — —
(3.54)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
— — — — — ‡‡‡‡‡ ‡‡‡‡ 0.48 0.16 0.03 — — —
Low Price
— — — — — ‡‡‡‡‡ ‡‡‡‡‡ 4.00 1.96 0.43 — — —
High Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 225 233 85 — — —
Employees
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.03 0.24 — — —
Revenue/Emp
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.03 7.16 20.16 ‡‡‡‡‡ — —
Revenue
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (63.02%) (43.79%) 5.03% — — —
Gross Margin
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.85 (11.86) (4.54) ‡‡‡‡‡ — —
EBT
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 951.77% (165.52%) (22.50%) ‡‡‡ — —
EBT Margin
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (39.62) (81.66) (9.55) ‡‡‡‡‡ — —
Net Income
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.06 0.02 1.93 — — —
Depreciation
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.11 0.25 0.68 ‡‡‡‡‡ — —
Revenue/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.40) (2.81) (0.32) ‡‡‡‡ — —
Earnings/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.12) (2.17) (1.06) — — —
Cash Flow/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.01) 0.00 ‡‡‡ — —
Capex/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.13) (2.18) (1.07) — — —
Free CF/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.63 (0.03) (0.39) — — —
Book Value/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.47 29.10 29.77 ‡‡‡‡‡ — —
Shares
— — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 ‡‡‡‡‡ — —
PE Ratio
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.06 0.85 0.09 ‡‡‡ — —
PS Ratio
— — — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.53 0.00 0.00 ‡‡‡ — —
PB Ratio
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.62) 1.56 1.01 ‡‡‡‡ — —
EV/Sales
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 (0.18) (0.64) — — —
EV/FCF
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (88.92) (63.12) (31.66) ‡‡‡ — —
Op' Cash Flow
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.23) (0.22) (0.11) — — —
Capex
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (89.14) (63.34) (31.77) — — —
FCF
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 98.00 27.31 13.14 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.75 34.52 32.57 — — —
Total Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.46) 5.09 18.55 — — —
Net Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 75.02 (0.88) (11.59) — — —
Sh' Equity
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.13%) (87.15%) (23.11%) ‡‡‡ — —
ROA
— — — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 76.43% (174.27%) (0.51%) — — —
ROIC
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.84%) (220.29%) 153.11% ‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Acutus Medical, Inc. (AFIB) Latest News

News by impact score

Fine-tune

24 Mar

4 GlobeNewswire, 4:01 PM
Acutus Medical, Inc. reported a 181% increase in revenue from continuing operations for 2024, totaling $20.2 million, with a reduced operating loss of $0.1 million compared to $11.7 million in 2023. The company recorded a $10.8 million gain on the sale of a business and improved gross margin to 5% from negative 44% the previous year. Cash and equivalents stood at $14.0 million as of December 31, 2024. Losses from discontinued operations decreased significantly to $5.0 million from $69.7 million in 2023. Acutus will no longer provide financial guidance as it realigns resources to focus on left-heart access products. The significant revenue growth and strategic realignment towards left-heart access products indicate a major shift in the company's trajectory.

4 Dec

3 , 4:01 PM
Acutus Medical, Inc. (AFIB) announces operational downsizing. The downsizing may moderately influence the company's financial performance and competitive positioning.

14 Nov

4 GlobeNewswire, 4:26 PM
Acutus Medical, Inc. reported significant revenue growth and improved operating income in the third quarter of 2024, with cash reserves of $12.6 million as of September 30. The company will no longer provide financial guidance due to restructuring plans. The financial results and strategic changes outlined in the article are expected to have a significant impact on Acutus Medical, Inc.'s future trajectory and market performance.

8 Aug

4 GlobeNewswire, 4:56 PM
Acutus Medical, Inc. reported significant revenue growth and reduced operating expenses in the second quarter of 2024, with a focus on left-heart access products. The financial results and strategic realignment are expected to have a significant impact on Acutus Medical's future performance and market positioning.

4 Insider Monkey, 1:52 PM
Acutus Medical, Inc. (NASDAQ:AFIB) Q2 2023 earnings call transcript reveals missed earnings expectations with reported EPS of $-0.63. Significant impact likely on future performance due to strong procedure volumes, new product launches, and financial progress.

4 Thomson Reuters StreetEvents, 6:17 AM
Acutus Medical, Inc. reports record procedure volumes and revenue growth in Q2 2023, driven by new product launches and increased user adoption. The significant growth in procedure volumes, revenue, and user adoption is expected to have a significant impact on Acutus Medical's future performance and market positioning.

9 May

3 GlobeNewswire, 4:01 PM
Acutus Medical reports 192% revenue growth in Q1 2024, with $3.6 million revenue and $2.1 million net loss. The financial results show a significant improvement in revenue and reduction in net loss, indicating a moderately noticeable influence on the company's financial performance.

3 Apr

3 Simply Wall St., 7:02 AM
Acutus Medical reports US$0.41 loss per share in FY 2023, improved from US$1.40 loss in FY 2022. The financial results show a moderately noticeable influence on Acutus Medical's future performance.

1 Apr

3 GlobeNewswire, 4:05 PM
Acutus Medical reports fourth quarter and full year 2023 financial results, focusing on strategic realignment and corporate restructuring. The financial results and strategic realignment are expected to moderately influence Acutus Medical's future operations and market performance.

10 Nov

4 www.medtechdive.com, 12:21 AM
Acutus Medical is laying off 65% of employees to focus solely on Medtronic heart device deal. The strategic shift to focus on the Medtronic partnership and lay off a significant portion of employees is a major move that could significantly impact Acutus Medical's future trajectory.

8 Nov

4 GlobeNewswire, 4:00 PM
Acutus Medical realigns resources and restructures to focus on manufacturing left-heart access products for Medtronic, winding down EP mapping and ablation business. The strategic realignment and corporate restructuring significantly impact the company's operations and future trajectory by shifting focus to a new business model.

3 GuruFocus.com, 6:42 PM
Acutus Medical Inc (AFIB) reports substantial revenue growth in Q3 2023 despite negative gross margin. The company showed significant revenue growth and improved operational efficiency, but challenges like negative gross margin remain.

3 GlobeNewswire, 4:01 PM
Acutus Medical reported third quarter 2023 financial results, showing revenue growth and reductions in operating expenses. The financial results and strategic realignment are expected to moderately influence the company's future performance.

2 Nov

3 GlobeNewswire, 4:13 PM
Acutus Medical, Inc. to announce third quarter 2023 financial results on November 13, 2023. The financial results announcement may moderately influence key areas such as financial performance and market sentiment.

7 Aug

4 , 4:01 PM
Acutus Medical, Inc. reports second quarter 2023 financial results with revenue growth, improved gross margin, and reduced operating expenses. The financial results and strategic initiatives are expected to significantly impact the company's future performance and market position.

3 Zacks, 5:40 PM
Acutus Medical, Inc. (AFIB) reported a Q2 loss but topped revenue estimates. The article discusses the company's financial performance and market outlook.

27 Jul

3 , 7:00 AM
Acutus Medical, Inc. (AFIB) will present at the 43rd Annual Canaccord Growth Conference. The presentation at the conference may moderately influence the company's competitive positioning and financial performance.

24 Jul

3 GlobeNewswire, 4:01 PM
Acutus Medical, Inc. to release second quarter 2023 financial results on August 7, 2023. The financial results announcement may moderately influence the company's financial performance and market sentiment.

16 May

4 Insider Monkey, 12:08 PM
Acutus Medical, Inc. beats earnings expectations with reported EPS of $-0.57 compared to expectations of $-0.69. The positive earnings report, new product launches, and clinical data presentations are expected to significantly impact Acutus Medical, Inc.'s future performance and market positioning.

15 May

4 GlobeNewswire, 9:00 AM
Acutus Medical to showcase innovative cardiac mapping and ablation technologies at HRS 2023. The article highlights significant advancements in Acutus Medical's technologies and their potential impact on the treatment of cardiac arrhythmias.

12 May

4 Thomson Reuters StreetEvents, 7:13 AM
Acutus Medical, Inc. reported Q1 2023 earnings call with updates on procedure volumes, product pipeline, financial results, and outlook for the year. The updates on procedure volumes, product pipeline, and financial results are expected to have a significant impact on Acutus Medical, Inc.'s future performance and market positioning.

11 May

4 GlobeNewswire, 4:01 PM
Acutus Medical, Inc. reports first quarter 2023 financial results with revenue increase and improved financial performance. The financial results and outlook provided in the article suggest a significant impact on Acutus Medical, Inc.'s future performance and market positioning.

28 Apr

3 GlobeNewswire, 5:15 PM
Acutus Medical, Inc. to announce first quarter 2023 financial results on May 11, 2023. The financial results announcement may moderately influence the company's financial performance and market sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us